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• Two distinct regions of
transmembrane somatic
mutations in type I cytokine
receptors IL7R and CRLF2







Gain-of-function somaticmutations introducing cysteines to either the extracellular or to
the transmembrane domain (TMD) in interleukin-7 receptor a (IL7R) or cytokine receptor-
like factor 2 (CRLF2) have been described in acute lymphoblastic leukemias. Here we
report noncysteine in-frame mutations in IL7R and CRLF2 located in a region of the TMD
closer to the cytosolic domain. Biochemical and functional assays showed that these
are activatingmutations conferring cytokine-independent growthof progenitor lymphoid
cells in vitro and are transforming in vivo. Protein fragment complementation assays
suggest that despite the absence of cysteines, the mechanism of activation is through
ligand-independent dimerization. Mutagenesis experiments and ConSurf calculations
suggest that the mutations stabilize the homodimeric conformation, positioning the
cytosolic kinases in predefined orientation to each other, thereby inducing spontaneous
receptor activation independently of external signals. Hence, type I cytokine receptors
may be activated in leukemia through 2 types of transmembrane somatic dimerizing
mutations. (Blood. 2014;124(1):106-110)
Introduction
Interleukin-7 receptor a (IL7R) dimerizes with cytokine receptor-
like factor 2 (CRLF2) to form the receptor for thymic stromal
lymphopoietin and with interleukin-2 receptor g to form the
receptor for IL-7.1,2 We and others described acquired activating
mutations in acute lymphoblastic leukemias (ALL) that insert
cysteines into the juxtamembrane domains of IL7R or CRLF2
causing ligand independent dimerization via disulﬁde bonds.3-5
The creation of disulﬁde bonds is critical for the activation of the
receptors because elimination of the cysteines abrogated the
cytokine independent growth.4,6,7
Here we report and analyze a novel class of noncysteine mutations




All specimens were collected with an informed consent and the approval
of ethics committees.4 Samples were anonymized for the study. The study
was approved by the Israeli Health Ministry Ethic committee, approval
# 920070771.
Molecular studies
Mutation detection and analysis using appropriate primers (supplemental
Table 1; see supplemental Data available at the Blood Web site). was
performed as described.4,8 The human IL7R cloned into the MSCV-IRES-
GFP and the human CRLF2 cloned into pMX-Puro retroviral vectors were
Submitted September 30, 2013; accepted April 20, 2014. Prepublished online
as Blood First Edition paper, May 1, 2014; DOI 10.1182/blood-2013-10-
529685.
The online version of this article contains a data supplement.
There is an Inside Blood Commentary on this article in this issue.
The publication costs of this article were defrayed in part by page charge
payment. Therefore, and solely to indicate this fact, this article is hereby
marked “advertisement” in accordance with 18 USC section 1734.
© 2014 by The American Society of Hematology
106 BLOOD, 3 JULY 2014 x VOLUME 124, NUMBER 1
used as templates for the generation ofmutations by site-directedmutagenesis
(QuikChange; Stratagene).
BaF3 cells were transduced with retroviruses and were sorted by ﬂow
cytometry (FACSAria; BD Biosciences) 2 to 4 days later using appropriate
antibodies. BaF3 growth assays and immunoprecipitation and western
analyses were performed as described previously.9
Protein fragment complementation assay
Mutated and wild-type (WT) cDNAs of human IL7R, CRLF2, and
interleukin-2 receptor g were inserted in pcDNA3.1/Zeo vector upstream of
either the hGluc1 or hGluc2 fragments of Gaussia princeps luciferase10 and
were cotransfected into HEK293 cells (see supplemental Methods). Signal
intensities were read on an Inﬁnite 200 reader (TECAN).
In vivo experiments
Six-week-old female Balb/c mice were injected intravenously with 1*106
BaF3 cells transducedwith eitherWTormutatedCRLF2or IL7R. Survival of
themicewasmonitored, and tissues from the sickmicewere subjected to ﬂow
cytometry analysis (Galios; Coulter Inc.).
Results and discussion
During our previously reported screens of childhood ALLs4,8 we
identiﬁed mutations in IL7R and in CRLF2 that did not introduce
cysteines (Figure 1A). All mutations were heterozygous, somatic,
and the mutated mRNA was expressed (Figure 1B). Examination of
published data showed additional similar mutations in IL7R (supple-
mental Table 2). These mutations cluster within a transmembranous
region internal to the area afﬂicted by the cysteine mutations
(Figure 1A; supplemental Figure 1). To test if the somatic mutations
in IL7R and CRLF2 are gain-of-function mutations, BaF3 lines
expressing either WT or mutated IL7R or CRLF2 were created. All
proteinswere expressed at the cellmembrane (supplemental Figure 2).
Mutated IL7RinsEKV, IL7RV253G, andCRLF2ins EIM enabled cytokine-
independent growth of BaF3 cells. CRLF2insEIM required the formation
of the thymic stromal lymphopoietin receptor by coexpression of
IL7RWT (Figure 1C,D). One construct IL7RinsGEA did not transform
BaF3 (Figure 1C). The transforming activity was conﬁrmed in vivo in
syngeneic Balb/cmice that developed fatal leukemia after intravenous
Figure 1. Noncysteine mutations in IL7R and CRLF2 are transforming leukemogenic mutations. (A) Predicted transmembrane domain (TMD) of IL7R and CRLF2 with
location of cysteine mutations (orange box) and noncysteine mutations (green box) and alignment of WT and mutated TMD sequences. Numbers show the positions of
nucleotides and corresponding amino acids. The inserted nucleotides and amino acids are shown in red. (B) Expression of CRLF2InsEIM mutation. The mutated allele is
expressed in the RNA from diagnosis whereas only the normal allele is found in the remission DNA sample because CRLF2 is expressed only in leukemic B-cell as a result of
a chromosomal rearrangement.8 (C,D) Cytokine withdrawal assay of BaF3 cells transduced with mutated or WT IL7R or CRLF2. (E) Overall survival of mice (7 mice in each
group, 3 experiments) injected intravenously with 1-2*106 BaF3 cells expressing IL7R, WT or mutant, or IL7RWT and CRLF2insEIM compared by Kaplan-Meier analysis
P # .01. (F) Representative flow cytometric analysis of blood from mice injected intravenously with 1-2*106 BaF3 cells expressing IL7RV253G. (G) Lymphoma tumor (top)
observed in a mouse injected subcutaneously with 1-2*106 BaF3 cells expressing IL7RIns EKV-GFP. Representative GFP expression from lymphoma cells (bottom).
(H) Representative analysis of cells from spleen and bone marrow from mice injected intravenously with 1-2*106 BaF3 cells expressing IL7RIns EKV and sacrificed at day 14.
(I) Representative analysis of cells from spleen and bone marrow from mice injected intravenously with 1-2*106 BaF3 cells coexpressing the IL7RWT and CRLF2WT or
CRLF2insEIM mutant, and sacrificed at day 16. Del, deletion; Ins, insertion; WT, wild type.
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injections of BaF3 cells expressing IL7RinsEKV, IL7RV253G, or
CRLF2insEIMIL7RWT (Figure 1E), manifested by inﬁltration of the
blood (Figure 1F), bone marrow, and spleen (Figure 1H-I) with the
transformed cells. Similarly, subcutaneous injection caused lymphoma
(Figure 1G). Thus noncysteine mutational activation of IL7R and
CRLF2 is leukemogenic.
Biochemical analysis was consistent with the growth assays. Stat5
(Figure 2A), Jak1, Jak2, and Stat3 (Figure 2B) were phosphorylated
in the absence of cytokine in BaF3 cells transduced with the
IL7RinsPPCL (positive control that constitutively activates the JAK-
STAT pathway),4 IL7RV253G, and IL7RinsEKV but not in cells
expressing IL7RWT or IL7RinsGEA. In IL7RinsEKV we found higher
expression of Jak2, which correlated with the higher activation capacity
of this mutant in BaF3 cytokine withdrawal assays. Similarly,
coexpression of IL7RWT with CRLF2insEIM, but not the expression
of CRLF2insEIM by itself, caused constitutive phosphorylation of
Stat5 and Jak2 (Figure 2C,D) consistent with the known binding of
Jak2 to CRLF211.
To assess whether the functional and biochemical evidence of
receptor activation is associated with the oligomerization of IL7R
and CRLF2 mutated proteins in cell membranes, we used the
luciferase protein fragment complementation assay10 (supplemental
Figure 3A). HEK293 cells were transduced with homodimeric or
heterodimeric combinations of IL7R and CRLF2 fused to hGluc1 or
hGluc2 (supplemental Figure 3B). After transduction, luciferase
expression and receptor expression were analyzed in live cells
(supplemental Figure 4). Dimerization was calculated by dividing
luminescence by the mean ﬂuorescence intensity of each receptor
thereby enabling normalization of the luminescence signal for
experimental variability resulting from transfection efﬁciency.
Figure 2. Noncysteine mutations in IL7R and CRLF2 cause constitutive activation of the JAK-STAT pathway and increase receptor dimerization. (A) Constitutive
phosphorylation of Stat5 in BaF3 cells expressing IL7R mutants after 5 hours of cytokine deprivation. One mutant with insertion of cysteine (IL7RinsPPCL) was used as a positive
control. IL-31 indicates cells harvested after 5 hours of IL-3 deprivation followed by 20 minutes of IL-3 stimulation. (B) Identification of constitutive phosphorylation of Jak1,
Jak2, and Stat3 in BaF3 cells expressing IL7R mutants after 5 hours of cytokine deprivation. IL-31 indicates cells harvested after 5 hours of IL-3 deprivation followed by
20 minutes of IL-3 stimulation. Cells were subjected to lysis and immunoprecipitation with anti p-Tyr antibody (sc-508; Santa Cruz Biotechnology). The presence of Jak1, Jak2,
and Stat3 was visualized by western blotting with anti-Jak1/Jak2/Stat3 antibodies. (C) Constitutive phosphorylation of Stat5 in BaF3 cells expressing CRLF2 mutant after 5
hours of cytokine deprivation. IL-31 indicates cells harvested after 5 hours of IL-3 deprivation followed by 20 minutes of IL-3 stimulation. (D) Identification of constitutive
phosphorylation of Jak2 and Stat5 in BaF3 cells expressing CRLF2 mutants after 5 hours of cytokine deprivation. IL-31 indicates cells harvested after 5 hours of IL-3
deprivation followed by 20 minutes of IL-3 stimulation. Cells were subjected to lysis and immunoprecipitation with anti p-Tyr antibody (sc-508; Santa Cruz Biotechnology). The
presence of Jak2 and Stat5 was visualized by western blotting with anti-Jak2 or Stat5 antibodies. (E) Relative dimerization level of IL7R and CRLF2 from HEK293 cells
transiently transfected with the WT or mutant receptor. Dimerization was calculated by dividing luminescence by the mean fluorescence intensity of each treatment,
normalizing the luminescence signal for experimental variability resulting from transfection efficiency. * P , .01, 1-way ANOVA, and Student t test. (F) Alignment of WT,
natural mutant (EKV), and 6 experimental mutants (numbered 1 to 6) in the TMD of IL7R. Numbers show the positions of nucleotides and corresponding amino acids. The
inserted nucleotides and amino acids are shown in red. The deleted AL amino acids are shown in green. (G) Cytokine withdrawal assay of BaF3 cells transduced with IL7R
experimental mutants. (H) Constitutive phosphorylation of Stat5 in BaF3 cells expressing IL7R experimental mutants after 5 hours of cytokine deprivation. IL-31 indicates
cells harvested after 5 hours of IL-3 deprivation followed by 20 minutes of IL-3 stimulation. Del, deletion; Ins, insertion.
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Consistent with the requirement of complementation for luciferase
expression, none of the single-receptor hGluc1 or hGluc2 constructs
that were individually transfected inHEK293 cells generated a signal
(supplemental Figure 3C). Yet when the IL7RWT homodimer or
heterodimer was expressed, a signal was obtained reﬂecting a basal
level of receptor dimerization, as recently reported.12 We then anal-
yzed the inﬂuence of the somatic mutations of IL7R and CRLF2 on
receptor dimerization.As shown inFigure2E, IL7Rins EKV, IL7RV253G,
and CRLF2insEIM increased receptors dimerization (P , .05)
whereas the IL7RinsGEA mutant that failed to provide cytokine-
independent survival of BaF3 cells, or to cause Stat5 phosphorylation,
alsodidnot increase receptor dimerization (Figure 2E). Thinking that it
may be a “passenger”mutation, we looked for additional activating
mutations but found none (supplemental Table 3).
As CRLF2insEIM alone increased receptor dimerization but did
not induce downstream constitutive signaling or transformed BaF3
cells, we concluded that there is no absolute correlation between
dimerization and activation.
We next proceeded to decipher the amino acids that are important
for the highly activating IL7RinsEKVmutation.We designed 6 variants
of the EKV mutation: AKV, EAV, EKA, EK, KV (including DelAL
like the naturalmutation), and insV (Figure 2F).BaF3 lines expressing
each variant were created (supplemental Figure 5). The variants
IL7RinsEAV and IL7RinsEKA enabled cytokine-independent growth
of BaF3 cells, whereas IL7RinsAKV, IL7RinsEK, IL7RinsKV, and
IL7RinsV did not transform BaF3 (Figure 2G). Biochemical analysis
was consistent with the growth assays. Stat5 was phosphorylated in
the absence of cytokine inBaF3 cells transducedwith the IL7RinsEAV
and IL7RinsEKA but much less in cells expressing IL7RinsAKV,
IL7RinsEK, IL7RinsKV, and IL7RinsV (Figure 2H).
ConSurf13 calculations with IL7R showed that the TMD segment
manifests a unique evolutionary conservation pattern with i/i14
periodicity, equivalent to that of a perfect a-helix (supplemental
Figure 6). The conserved positions would reside in the same helix
face, providing an interface for IL7R homodimerization. All of the
natural and experimental mutations can be interpreted assuming that
activation requires IL7R dimerization with the cytosolic kinases in
predeﬁned orientation with respect to each other. The conserved face
of the TMD helix in WT IL7R marks the orientation. Dimerization
along a different TMDhelix facewould not activate because the kinases
will not be facing each other. Molecular detailed interpretations of
the mutations’ effect are provided in supplemental Figures 7 and 8
and supplemental Table 4.
Taken together, these data indicate that the functional and bio-
chemical evidence for receptor activation by mutations lacking
cysteine correlates with ligand independent dimerization. There are
several examples of TMD mutations in receptors that cause constitu-
tive activation without introducing cysteine: V664E in the Neu
receptor tyrosine kinase14-16 and the dimerization inducing muta-
tions in MPL17,18 that was identiﬁed in rare familial thrombocytosis
patients.19 Our observations of noncysteine transmembrane muta-
tions in type I cytokine receptors in patients with ALL demonstrate
for the ﬁrst time that such somatic mutations activate these receptors
through ligand-independent dimerization and are leukemogenic.
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